{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T09:33:36Z","timestamp":1793180016997,"version":"4.5.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1097\/wnf.0000000000000017","type":"journal-article","created":{"date-parts":[[2014,1,16]],"date-time":"2014-01-16T03:50:19Z","timestamp":1389844219000},"page":"26-30","source":"Crossref","is-referenced-by-count":101,"title":["A D1 Receptor Antagonist, Ecopipam, for Treatment of Tics in Tourette Syndrome"],"prefix":"10.1097","volume":"37","author":[{"given":"Donald L.","family":"Gilbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy L.","family":"Budman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey S.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Kurlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Chipkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-6-20210203","first-page":"89","article-title":"Neurobiology of basal ganglia and Tourette syndrome: basal ganglia circuits and thalamocortical outputs.","volume":"99","year":"2006","journal-title":"Adv Neurol"},{"key":"R5-6-20210203","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1474-4422(05)70018-1","article-title":"Tourettes syndrome: from behaviour to biology.","volume":"4","year":"2005","journal-title":"Lancet Neurol"},{"key":"R8-6-20210203","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0887-8994(01)00262-4","article-title":"Basal ganglia dysfunction in Tourettes syndrome: a new hypothesis.","volume":"25","year":"2001","journal-title":"Pediatr Neurol"},{"key":"R13-6-20210203","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0014-2999(88)90492-X","article-title":"Comparison of the pharmacological characteristics of 3Hraclopride and 3HSCH 23390 binding to dopamine receptors in vivo in mouse brain.","volume":"146","year":"1988","journal-title":"Eur J Pharmacol"},{"key":"R21-6-20210203","first-page":"218","article-title":"Clinical global impression scale. The ECDEU Assessment Manual for Psychopharmacology-Revised.","volume":"338","year":"1976","journal-title":"Volume DHEW Publ No ADM"},{"key":"R24-6-20210203","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression.","volume":"23","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R32-6-20210203","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1124\/jpet.104.074468","article-title":"Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1SvJ, C57BL6J, and DBA2J mice.","volume":"312","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"R36-6-20210203","first-page":"29","article-title":"Risperidone as a treatment for Tourettes syndrome.","volume":"57","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"R40-6-20210203","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1176\/jnp.17.3.324","article-title":"Assessment of scientific and ethical issues in two randomized clinical trial designs for patients with Tourettes syndrome: a model for studies of multiple neuropsychiatric diagnoses.","volume":"17","year":"2005","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R44-6-20210203","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/1531-8257(200011)15:6<1194::AID-MDS1019>3.0.CO;2-H","article-title":"Response to levodopa challenge in Tourette syndrome.","volume":"15","year":"2000","journal-title":"Mov Disord"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WNF.0000000000000017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:09:34Z","timestamp":1620961774000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-201401000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0000000000000017","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725857335.793513709","asserted-by":"object"}]},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}